DSP Mutual Fund
When comparing, both lines start at 100. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare TRI) is not available to us as a series.
This is an IDCW (dividend) option: it pays cash out of its NAV, so returns computed from the NAV alone would understate what an investor earned. See the Growth option of the same plan for performance.
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. Shown from the Direct plan of this fund, which holds the same portfolio. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| IPCA Laboratories Limited | Healthcare | 8.74% | — | 39.3 |
| Sun Pharmaceutical Industries Limited | Healthcare | 7.95% | — | 146.5 |
| Sai Life Sciences Limited | Healthcare | 7.45% | — | 90.6 |
| Cipla Limited | Healthcare | 7.35% | — | 35.4 |
| Apollo Hospitals Enterprise Limited | Healthcare | 6.47% | — | 74.7 |
| Gland Pharma Limited | Healthcare | 5.98% | — | 34.3 |
| Globus Medical Inc | — | 5.44% | — | — |
| Divi's Laboratories Limited | Healthcare | 4.15% | — | 83.9 |
| Alkem Laboratories Limited | Healthcare | 4.08% | — | 28.9 |
| Cohance Lifesciences Limited | Healthcare | 3.81% | — | 95.7 |
| TREPS / Reverse Repo Investments | — | 3.77% | — | — |
| Manipal Health Enterprises Limited | Healthcare | 3.70% | — | — |
| Pfizer Limited | Healthcare | 3.22% | — | 24.1 |
| Alembic Pharmaceuticals Limited | Healthcare | 3.14% | — | 22.1 |
| Kovai Medical Center And Hospital Limited | Healthcare | 2.80% | — | 25.6 |
| Concord Biotech Limited | Healthcare | 2.77% | — | 51.0 |
| Vijaya Diagnostic Centre Limited | Healthcare | 2.44% | — | 76.7 |
| Procter & Gamble Health Limited | Healthcare | 2.40% | — | 25.9 |
| Thyrocare Technologies Limited | Healthcare | 2.11% | — | 34.1 |
| Indoco Remedies Limited | Healthcare | 2.06% | — | 23.1 |
| Intuitive Surgical Inc | — | 1.76% | — | — |
| Unichem Laboratories Limited | Healthcare | 1.64% | — | 23.1 |
| Syngene International Limited | Healthcare | 1.31% | — | 64.2 |
| Nephrocare Health Services Limited | Healthcare | 1.13% | — | — |
| ICICI Lombard General Insurance Co Limited | Financial Services | 0.99% | — | — |
| Global X Funds - Global X Genomics & Biotechnology ETF | — | 0.98% | — | — |
| Aarti Drugs Limited | Healthcare | 0.91% | — | 22.9 |
| Abbott Laboratories | — | 0.87% | — | — |
| Eris Lifesciences Limited | Healthcare | 0.76% | — | 84.7 |
| Jupiter Life Line Hospitals Limited | Healthcare | 0.40% | — | 9.0 |
| Grail Inc | — | 0.17% | — | — |
| Laxmi Dental Limited | Healthcare | 0.14% | — | 59.4 |
This is a paid feature
Comparing more months of this fund's own portfolio history is available on paid plans.
Sign inExpense ratio by month: Oct 25 1.91% · Nov 25 1.91% · Dec 25 1.92% · Jan 26 1.94% · Feb 26 1.94% · Mar 26 1.94% · Apr 26 2.12% · May 26 1.92% · Jun 26 1.97% · Jul 26 2.02% · Aug 26 2.04% · Sep 26 2.05%
0.50% - Holding period from the date of allotment <= 1 month, Nil - Holding period from the date of allotment > 1 month (as a % of Applicable NAV)
The primary investment objective of the scheme is to seek to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies/entities. There is no assurance that the investment objective of the Scheme will be achieved.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
